WEREWOLF THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-11-04
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was -$124.00K.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $124.00K, a 32.97% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $76.00K, a 31.53% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $111.00K, a 40.51% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $79.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | |||
| 2024-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 derived: sum of 3 quarters · filed 2025-11-04 | $0.00 10-K · filed 2025-03-11 |
| 2024-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $124.00K derived: sum of 2 quarters · filed 2025-11-04 | $124.00K 10-Q · filed 2025-11-04 | $2.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$122.00K derived: sum of 3 quarters · filed 2025-03-11 | $63.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-03 | -$122.00K derived: sum of 2 quarters · filed 2025-03-11 | $63.00K derived: sum of 3 quarters · filed 2025-03-11 | -$3.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | -$122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $63.00K derived: sum of 2 quarters · filed 2025-03-11 | -$3.00K derived: sum of 3 quarters · filed 2025-03-11 | $76.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $119.00K derived: sum of 2 quarters · filed 2024-11-07 | $198.00K 10-Q · filed 2024-11-07 | $2.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.00K 10-Q · filed 2024-08-08 | -$183.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.76M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $79.00K 10-Q · filed 2024-05-03 | -$117.00K derived: sum of 2 quarters · filed 2024-05-03 | -$1.69M derived: sum of 3 quarters · filed 2024-05-03 | -$1.36M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | -$196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$1.77M derived: sum of 2 quarters · filed 2024-03-07 | -$1.44M derived: sum of 3 quarters · filed 2024-03-07 | $111.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$1.25M derived: sum of 2 quarters · filed 2023-11-14 | $307.00K 10-Q · filed 2023-11-14 | $306.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $329.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.88M 10-Q · filed 2023-08-10 | $1.88M derived: sum of 3 quarters · filed 2023-08-10 | $1.95M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.55M 10-Q · filed 2023-05-11 | $1.55M derived: sum of 2 quarters · filed 2023-05-11 | $1.62M derived: sum of 3 quarters · filed 2023-05-11 | $1.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $64.00K derived: sum of 2 quarters · filed 2023-03-23 | -$51.00K derived: sum of 3 quarters · filed 2023-03-23 | $79.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$50.00K derived: sum of 2 quarters · filed 2022-11-10 | $80.00K 10-Q · filed 2022-11-10 | $80.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $15.00K 10-Q · filed 2022-08-11 | $15.00K derived: sum of 3 quarters · filed 2022-08-11 | -$11.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $130.00K 10-Q · filed 2022-05-10 | $130.00K derived: sum of 2 quarters · filed 2022-05-10 | $104.00K derived: sum of 3 quarters · filed 2022-05-10 | $64.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$26.00K derived: sum of 2 quarters · filed 2022-03-24 | -$66.00K derived: sum of 3 quarters · filed 2022-03-24 | $0.00 10-K · filed 2022-03-24 |
| 2020-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$66.00K derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $26.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $66.00K 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |